Skip to main content
    C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.67
    -0.19 (-1.93%)

    Market Cap: $387.16M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49, below the -$0.45 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(5/11)
    Avg Surprise
    -18.77%

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.50
    Range-$0.54 - -$0.35
    10 analysts
    Revenue Consensus
    N/A
    RangeN/A
    8 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.47
    Range-$0.54 - -$0.39
    3 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.46-1.4%
    60d ago-$0.46-1.4%
    30d ago-$0.45-4.4%
    7d ago-$0.43-9.3%
    Current-$0.47
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Next Report

    CTNM has an expected report date of Mar 3, 2027.

    Earnings History

    Of the 11 quarters below that had an estimate, CTNM beat 5 and missed 6. The widest gap in the table came in the quarter ended Mar 31, 2024, when EPS landed 166.92% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.49-$0.45-$0.51 - -$0.40-8.89%MissN/A73 up, 3 downNov 3, 2026
    Jun 30, 2026-$0.40-$0.46-$0.51 - -$0.38+13.04%BeatN/A77 up, 0 downJul 30, 2026
    Mar 31, 2026-$0.39-$0.53-$0.61 - -$0.46+26.42%BeatN/A71 up, 2 downMay 5, 2026
    Dec 31, 2025-$0.49-$0.65N/A+24.62%BeatN/A72 up, 0 downMar 5, 2026
    Sep 30, 2025-$0.45-$0.46-$0.70 - $0.40+2.17%BeatN/A74 up, 1 downOct 30, 2025
    Jun 30, 2025-$0.62-$0.41-$0.69 - $0.42-51.22%MissN/A61 up, 4 downAug 5, 2025
    Mar 31, 2025-$0.62-$0.57-$0.61 - -$0.51-8.77%MissN/A50 up, 0 downMay 14, 2025
    Dec 31, 2024-$0.56-$0.43-$0.50 - -$0.37-30.23%MissN/A4N/AMar 6, 2025
    Sep 30, 2024-$0.40-$0.42-$0.43 - -$0.35+4.76%BeatN/A40 up, 0 downNov 6, 2024
    Jun 30, 2024-$0.39-$0.35N/A-11.43%MissN/AN/AN/AAug 13, 2024
    Mar 31, 2024-$3.55-$1.33N/A-166.92%MissN/AN/AN/AMay 16, 2024
    Dec 31, 2023-$1.44N/AN/AN/AN/AN/AN/AN/AFeb 28, 2024
    Last 12 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.18, after -$4.90 the year before. It was -$1.44 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.18N/A
    Dec 31, 2024-$4.90N/A
    Dec 31, 2023-$1.44N/A

    Frequently Asked Questions About CTNM

    When is Contineum Therapeutics, Inc. Class A Common Stock's next earnings date?

    Contineum Therapeutics, Inc. Class A Common Stock's next earnings report is expected for Mar 3, 2027.

    Did CTNM beat earnings estimates last quarter?

    No. Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49 for the quarter ended Sep 30, 2026, below the -$0.45 estimate by 8.89%.

    What EPS do analysts expect from CTNM next quarter?

    The consensus EPS estimate for Contineum Therapeutics, Inc. Class A Common Stock for the quarter ending Dec 31, 2026 is -$0.50 from 10 analysts, with estimates from -$0.54 to -$0.35.

    How often does CTNM beat earnings estimates?

    Contineum Therapeutics, Inc. Class A Common Stock beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.11%.